Aduro BioTech (NASDAQ:ADRO) Rating Increased to Sell at BidaskClub

BidaskClub upgraded shares of Aduro BioTech (NASDAQ:ADRO) from a strong sell rating to a sell rating in a research note published on Tuesday, January 23rd.

Other analysts have also issued reports about the company. Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the company a buy rating in a research note on Thursday, December 14th. HC Wainwright set a $10.00 target price on Aduro BioTech and gave the company a buy rating in a research note on Tuesday, December 19th. William Blair reiterated an outperform rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, Oppenheimer lowered their price objective on Aduro BioTech from $15.00 to $13.00 and set an outperform rating for the company in a research report on Wednesday, December 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Aduro BioTech presently has an average rating of Buy and an average target price of $17.71.

Shares of Aduro BioTech (NASDAQ:ADRO) traded up $0.05 during midday trading on Tuesday, hitting $6.25. The company’s stock had a trading volume of 370,744 shares, compared to its average volume of 518,951. The company has a market capitalization of $483.15, a PE ratio of -4.60 and a beta of 3.01. Aduro BioTech has a 12 month low of $5.82 and a 12 month high of $14.05.

In other news, VP Jennifer Lew sold 6,600 shares of Aduro BioTech stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $9.46, for a total transaction of $62,436.00. Following the transaction, the vice president now owns 68,938 shares in the company, valued at approximately $652,153.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dirk G. Brockstedt sold 10,000 shares of Aduro BioTech stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $9.40, for a total value of $94,000.00. Following the transaction, the executive vice president now owns 77,674 shares in the company, valued at approximately $730,135.60. The disclosure for this sale can be found here. Insiders have sold a total of 172,899 shares of company stock valued at $1,488,733 over the last 90 days. Corporate insiders own 6.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its stake in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares in the last quarter. Voya Investment Management LLC lifted its stake in Aduro BioTech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares in the last quarter. Nationwide Fund Advisors lifted its stake in Aduro BioTech by 12.5% in the 2nd quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 2,567 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Aduro BioTech by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 3,769 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Aduro BioTech by 12.7% in the 2nd quarter. Alliancebernstein L.P. now owns 46,300 shares of the biotechnology company’s stock valued at $528,000 after acquiring an additional 5,200 shares in the last quarter. Institutional investors and hedge funds own 45.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/14/aduro-biotech-adro-upgraded-to-sell-by-bidaskclub.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply